News

Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.

The agency approved selpercatinib for the treatment of patients with advanced or metastatic, RET-mutant medullary thyroid cancer.

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

An oncology research nurse balances patient care with rigorous data collection, emphasizing communication and collaboration to advance cancer research.

The FDA approved osimertinib for locally advanced, unresectable stage III EGFR-mutated non-small cell lung cancer.

Neoadjuvant immune checkpoint inhibitors plus chemotherapy also improved efficacy outcomes in PD-L1-positive/ERBB2-negative tumors.

Distant relapse-free survival was maintained with non-operative management of pMMR locally advanced rectal cancer.

Chlorhexidine dressings, along with proper patient education, are key in preventing central line-associated blood stream infections in patients with cancer.

A group of advanced practice providers discuss treatment options for a woman with newly diagnosed, transplant-ineligible multiple myeloma.

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer with BRCA2 alterations.

Belrestotug plus dostarlimab-gxly improved ORR in patients with previously untreated, unresectable, locally advanced or metastatic, PD-L1–high NSCLC.

Nurses play a crucial role for patients with prostate cancer undergoing radiation treatment, according to a radiation oncology nurse.

Patients with metastatic castration-resistant prostate cancer who received radium-223 prior to docetaxel had better quality of life and tolerability scores than those who received docetaxel first.

A nurse practitioner discusses her role in caring for patients with multiple myeloma, and how advanced practice providers have a unique skillset to offer in cancer care.

Adagrasib outperformed docetaxel in patients with KRAS G12C-mutated non–small cell lung cancer, regardless of baseline brain metastases.

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF V600–positive melanoma.

Guiding treatment via response predictive subtype could be beneficial for identifying patients with high-risk breast cancer who may respond to Dato-DXd plus durvalumab.

Pembrolizumab led to improved survival over ipilimumab in patients with unresectable advanced melanoma, according to long-term data.

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who are ineligible for ASCT.

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma.

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in particular with the use of elacestrant, in HR-positive, HER2-negative metastatic breast cancer.

The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR TKI.

Trastuzumab deruxtecan improved time to deterioration for pain and other categories, in patients with HER2 low/ultralow breast cancer.

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine therapy.

Datopotamab deruxtecan(Dato-DXd) demonstrated antitumor activity in patients with advanced/metastatic ovarian or endometrial cancer who had prior chemotherapy treatment.

The FDA approved pembrolizumab plus pemetrexted and platinum chemotherapy for advanced or metastatic malignant pleural mesothelioma.

Zipalertinib was safe and effective for heavily pretreated patients NSCLC harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell lung cancer after disease progression on osimertinib.